Roche buys into Blueprint's RET inhibitor
Saturday, July 18, 2020 - 20:40
in Mathematics & Economics
The deal positions pralsetinib to compete against Lilly's Retevmo
Updated by artificial intelligence Tue, 13 Jun 2023, 2:53:47 UTC Learn more
- Tell your friends
- Get science news via